



## Announcement Summary

**Entity name**

NYRADA INC.

**Announcement Type**

New announcement

**Date of this announcement**

Tuesday January 21, 2025

**Details of +securities that have ceased**

<b>ASX +security code</b>	<b>Security description</b>	<b>Number of +securities that have ceased</b>	<b>The +securities have ceased due to</b>	<b>Date of cessation</b>
NYRAE	PERFORMANCE SHARES RESTRICTED	18,000,000	Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied	21/01/2025
NYRAH	OPTION EXPIRING VAR DATES RESTRICTED EX VAR PRICES	600,000	Expiry of option or other convertible security without exercise or conversion	18/01/2025
NYRAH	OPTION EXPIRING VAR DATES RESTRICTED EX VAR PRICES	7,600,000	Expiry of option or other convertible security without exercise or conversion	16/01/2025

Refer to next page for full details of the announcement



Part 1 - Announcement Details

---

**1.1 Name of +Entity**

NYRADA INC.

We (the entity named above) provide the following information about our issued capital.

**1.2 Registered Number Type**

ABN

**Registration Number**

54625401818

**1.3 ASX issuer code**

NYR

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

21/1/2025

For personal use only



Part 2 - Details of +equity securities or +debt securities that have ceased

**ASX +Security Code and Description**

NYRAH : OPTION EXPIRING VAR DATES RESTRICTED EX VAR PRICES

**Unquoted +equity securities that have ceased**

**Number of securities that have ceased**

600,000

**Reason for cessation**

Expiry of option or other convertible security without exercise or conversion

**Date of cessation**

18/1/2025

**Is the entity paying any consideration for the cessation?**

No

**Any other information the entity wishes to notify to ASX about the cessation?**

Tranche 1 of Director Options issued to director, Dr Ian Dixon, as previously approved by shareholders on 19 November 2020.

**ASX +Security Code and Description**

NYRAH : OPTION EXPIRING VAR DATES RESTRICTED EX VAR PRICES

**Unquoted +equity securities that have ceased**

**Number of securities that have ceased**

7,600,000

**Reason for cessation**

Expiry of option or other convertible security without exercise or conversion

**Date of cessation**

16/1/2025

**Is the entity paying any consideration for the cessation?**

No

**Any other information the entity wishes to notify to ASX about the cessation?**

Refer Section 10.5(C) of the prospectus dated 26 November 2019 (Prospectus).  
 (1) 3.6m Tranche 2 of Director Options issued to current and past directors as part of Prospectus; and  
 (2) 4.0m Tranche 1 of Kelly Options issued to Graham Kelly as part of Prospectus.

**ASX +Security Code and Description**

NYRAE : PERFORMANCE SHARES RESTRICTED

**Unquoted +equity securities that have ceased**

**Number of securities that have ceased**

5,999,400

For personal use only

**Reason for cessation**

Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied

**Date of cessation**

21/1/2025

**Is the entity paying any consideration for the cessation?**

Yes

**In what currency is the consideration being paid? Consideration amount per +security paid by the entity for the cessation**

AUD - Australian Dollar

AUD 0.000000166683

**Any other information the entity wishes to notify to ASX about the cessation?**

Further to the original terms of the Performance Shares ("PS"), the following redemption amount / aggregate consideration has been paid:

- (a) \$1 to Noxopharm Limited in respect of the 12,000,600 PS held; and
- (a) \$1 to Altnia Holdings PL in respect of the 5,999,400 PS held.

**ASX +Security Code and Description**

NYRAE : PERFORMANCE SHARES RESTRICTED

**Unquoted +equity securities that have ceased****Number of securities that have ceased**

12,000,600

**Reason for cessation**

Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied

**Date of cessation**

21/1/2025

**Is the entity paying any consideration for the cessation?**

Yes

**In what currency is the consideration being paid? Consideration amount per +security paid by the entity for the cessation**

AUD - Australian Dollar

AUD 0.000000083329

**Any other information the entity wishes to notify to ASX about the cessation?**

Further to the original terms of the Performance Shares ("PS"), the following redemption amount / aggregate consideration has been paid:

- (a) \$1 to Noxopharm Limited in respect of the 12,000,600 PS held; and
- (a) \$1 to Altnia Holdings PL in respect of the 5,999,400 PS held.



## Part 3 - Issued capital following changes

**Following the cessation of the +securities the subject of this notification, the issued capital of the entity will comprise:**

The figures in parts 3.1 and 3.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

**3.1 Quoted +equity securities and +debt securities (total number of each +class of +securities quoted on ASX)**

ASX +security code and description	Total number of +securities on issue
NYR : CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED	210,333,705

**3.2 Unquoted +equity securities (total number of each +class of +equity securities issued but not quoted on ASX)**

ASX +security code and description	Total number of +securities on issue
NYRAK : OPTION EXPIRING 31-DEC-2027 EX \$0.20	2,500,000
NYRAE : PERFORMANCE SHARES RESTRICTED	0
NYRAH : OPTION EXPIRING VAR DATES RESTRICTED EX VAR PRICES	20,600,000
NYRAI : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	10,100,000
NYRAJ : OPTION EXPIRING 30-JUN-2027 EX \$0.135	5,000,000

Note: the figures stated in the tables above are used to calculate the total market capitalisation of the entity published by ASX from time to time. The table will not include those classes of +securities that have ceased or lapsed in their entirety in ASX records before the announcement date described in Q1.5, even if the entity has advised ASX of a change to that class of +security in Part 2 of this form.